As we at Budding Trends reported last week, the DEA is set to finally accept the recommendation of the U.S. Department of Health and Human Services (HHS) to reschedule marijuana from Schedule I to Schedule III under the...more
5/7/2024
/ Administrative Law Judge (ALJ) ,
Cannabis Products ,
Congressional Review Act ,
Controlled Substances Act ,
DEA ,
Decriminalization of Marijuana ,
Department of Health and Human Services (HHS) ,
Final Rules ,
Judicial Review ,
Legislative Agendas ,
Marijuana ,
Marijuana Related Businesses ,
Medical Marijuana ,
Notice of Proposed Rulemaking (NOPR) ,
OMB ,
Public Comment ,
Regulatory Agenda ,
Schedule I Drugs ,
State and Local Government
While we enter a new season this week, the same cannot be said for the FDA which, on November 16, reiterated that its approach to regulating the cannabidiol (CBD) industry will be “the same as it ever was”—a regulatory...more
12/1/2021
/ Cannabidiol (CBD) oil ,
Cannabis Products ,
Cannabis-Related Businesses (CRBs) ,
Dietary Supplements ,
False Advertising ,
Food and Drug Administration (FDA) ,
Health and Safety ,
Labeling ,
Legislative Agendas ,
Medical Foods ,
Regulatory Oversight
On July 14, 2021, Senate Majority Leader Chuck Schumer (D-NY), Senate Finance Committee Chairman Ron Wyden (D-OR), and Sen. Cory Booker (D-NJ) unveiled a draft of the Cannabis Administration and Opportunity Act.
The...more